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Abstract: Performance and conflict monitoring (PM and CM) represent two essential cognitive abil-
ities, required to respond appropriately to demanding tasks. PM and CM can be investigated using
event-related brain potentials (ERP) and associated neural oscillations. Namely, the error-related neg-
ativity (ERN) represents a correlate of PM, whereas the N2 component reflects the process of CM.
Both ERPs originate in the anterior cingulate cortex (ACC) and PM specifically has been shown to
be susceptible to gamma-aminobutyric acid (GABA) A receptor activation. Contrarily, the specific ef-
fects of GABAB receptor (GABABR) stimulation on PM and CM are unknown. Thus, the effects of
gamma-hydroxybutyrate (GHB; 20 and 35 mg/kg), a predominant GABABR agonist, on behavioral
and electrophysiological correlates of PM and CM were here assessed in 15 healthy male volunteers, us-
ing the Eriksen–Flanker paradigm in a randomized, double-blind, placebo-controlled, cross-over study.
Electroencephalographic (EEG) data were analyzed in the time and time-frequency domains. GHB pro-
longed reaction times, without affecting error rates or post-error slowing. Moreover, GHB decreased
ERN amplitudes and associated neural oscillations in the theta/alpha1 range. Similarly, neural oscilla-
tions associated with the N2 were reduced in the theta/alpha1 range, while N2 amplitude was conversely
increased. Hence, GHB shows a dissociating effect on electrophysiological correlates of PM and CM.
Reduced ERN likely derives from a GABABR-mediated increase in dopaminergic signaling, disrupting
the generation of prediction errors, whereas an enhanced N2 suggests an increased susceptibility towards
external stimuli. Conclusively, GHB is the first drug reported, thus far, to have opposite effects on PM
and CM, underlined by its unique electrophysiological signature.
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Performance and conflict monitoring (PM and CM) represent two essential cognitive abilities, 
required to respond appropriately to demanding tasks. PM and CM can be investigated using 
event-related brain potentials (ERP) and associated neural oscillations. Namely, the error-
related negativity (ERN) represents a correlate of PM, whereas the N2 component reflects the 
process of CM. Both ERPs originate in the anterior cingulate cortex (ACC) and PM 
specifically has been shown to be susceptible to gamma-aminobutyric acid (GABA) A 
receptor activation. Contrarily, the specific effects of GABAB receptor (GABABR) 
stimulation on PM and CM are unknown. Thus, the effects of gamma-hydroxybutyrate (GHB; 
20 and 35 mg/kg), a predominant GABABR agonist, on behavioral and electrophysiological 
correlates of PM and CM were here assessed in 15 healthy male volunteers, using the 
Eriksen-Flanker paradigm in a randomized, double-blind, placebo-controlled, cross-over 
study. Electroencephalographic (EEG) data were analyzed in the time and time-frequency 
domains. GHB prolonged reaction times, without affecting error rates or post-error slowing. 
Moreover, GHB decreased ERN amplitudes and associated neural oscillations in the 
theta/alpha1 range. Similarly, neural oscillations associated with the N2 were reduced in the 
theta/alpha1 range, while N2 amplitude was conversely increased. Hence, GHB shows a 
dissociating effect on electrophysiological correlates of PM and CM. Reduced ERN likely 
derives from a GABABR-mediated increase in dopaminergic signaling, disrupting the 
generation of prediction errors, whereas an enhanced N2 suggests an increased susceptibility 
towards external stimuli. Conclusively, GHB is the first drug reported, thus far, to have 






Performance and conflict monitoring (PM and CM, respectively) represent two vital cognitive 
processes, required to appropriately interact with a continuously changing and demanding 
environment. On the one hand, PM is engaged in evaluating the accordance between an 
ongoing action and its original intent. Thus, erroneous actions can be readily detected and 
behavior can be adjusted in order to improve performance in response to future events 
(Devinsky et al, 1995). PM is typically investigated in terms of the error-related negativity 
(ERN), an event-related potential (ERP) elicited in the electroencephalogram (EEG), when 
subjects commit errors in speeded two-choice tasks (Falkenstein et al, 2000; Gehring et al, 
1995). More precisely, the ERN originates from a phase-resetting of frontomedial delta and 
theta oscillations and, accordingly, these oscillations were also found to be increased after 
error commission (Luu et al, 2004; Yordanova et al, 2004; Munneke et al, 2015). 
On the other hand, CM serves in the evaluation of conflicting response alternatives, enabling 
a dynamic recruitment of top-down neural resources that are needed to choose the most 
appropriate response (Yeung et al, 2004). CM can be assessed by means of the stimulus-
locked N2 ERP and associated frontal theta oscillations. Specifically, the amplitude of the N2 
is thought to reflect the conflict load arising from simultaneously active response tendencies, 
as its amplitude was repeatedly found to increase proportionally with the strength of the 
conflict (Yeung et al, 2004; Cavanagh et al, 2009). 
Both the ERN and the N2 reflect similar processes of a complex neural control system, with 
the anterior cingulate cortex (ACC) representing its core neural generator. The ACC is 
influenced by the striatal dopaminergic reward system and implements behavioral 
adjustments during PM and CM in conjunction with the dorsolateral prefrontal cortex 
(DLPFC) (Botvinick et al, 2001; Van Veen & Carter 2002; Holroyd et al, 2004; MacDonald 
2000). Importantly, the mesencephalic dopamine system (MCDS) plays a critical role in the 
activation of the ACC during error commission and response conflict. As proposed by the 
reinforcement learning theory, a “prediction error” is generated, when outcomes are worse 
than expected. This prediction error signal is then transmitted to the ACC via a phasic dip in 
the tonic activity of the MCDS, disinhibiting the ACC and thereby enabling behavioral 
adjustment (Holroyd et al, 2002; Schultz et al, 1997). Based on this notion of dopaminergic 
involvement in the generation of the ERN, many pharmacological studies have investigated 
the effects of drugs on PM and CM. Interestingly, while the ERN shows a high susceptibility 
to a wide range of pharmacological manipulations, the N2 seems to be more resistant to such 
	
	
interventions (Spronk et al, 2011, 2014). ERN amplitudes were found to be enhanced in 
subjects treated with the indirect dopamine agonist d-amphetamine, but N2 amplitudes 
remained unaffected (De Bruijn et al, 2004). In contrast, administration of antipsychotics such 
as haloperidol and olanzapine – both antagonists at dopaminergic receptors – reduced ERN 
amplitude, but again without affecting N2 magnitude (De Bruijn et al, 2006). Additionally, 
the involvement of gamma-aminobutyric acid-A receptors (GABAAR) in the process of PM 
has been demonstrated repeatedly, as indicated by reduced ERN amplitudes after treatment 
with positive GABAAR modulatory benzodiazepines or the full GABAAR agonist muscimol 
(Riba et al, 2005; De Bruijn et al, 2004; Shima 1998). Likewise, ethanol, with its modulatory 
effects on GABAAergic transmission, shows a blunting effect on the ERN (Spronk et al, 2014; 
Ridderinkhof et al, 2002). However, despite their effects on the ERN, neither benzodiazepines 
nor ethanol significantly affect N2 magnitude (De Bruijn et al, 2004; Riba et al, 2005; Riba et 
al, 2005). 
To our knowledge, no data are available that elucidate a role for GABABergic transmission in 
the processes of PM and CM. Therefore, we investigated the effects of gamma-
hydroxybutyrate (GHB), an endogenous short-chain fatty acid, on the behavioral and 
electrophysiological correlates of PM and CM in healthy volunteers. GHB has an agonistic 
action at GABAB and GHB receptors and its subjective and behavioral effects were shown to 
be predominantly mediated by GABABR (Nissbrandt & Engberg 1996; Carter et al. 2009). 
Given the similarity between GHB and GABAAergic drugs, we expected comparable effects 
on PM and CM to those reported for ethanol and benzodiazepines. Consequently, we 
hypothesized a blunting effect of GHB on PM indicated by reduced ERN amplitudes and a 
decreased spectral power in associated neural oscillations in the theta range. Given the 
repeatedly reported insusceptibility of the N2 to pharmacological manipulations, we expected 
no effects on CM, indicated by unaffected N2 amplitudes and spectral power in associated 
neural theta oscillations. As GHB has been reported to have both stimulant and sedative 
effects (Abanades et al, 2006; Bosch et al, 2018), no specific drug effects on behavioral 
outcomes were expected. Besides the relevance of this study for increased understanding of 
the role of GABABR in the processes of PM and CM, it is also of clinical relevance, as GHB 
has become a repurposing candidate for the treatment of major depressive disorder (Bosch et 
al, 2012), Parkinson’s (Ondo et al, 2008) and Alzheimer’s disease (Mamelak, 2007), which in 
turn have all been shown to be associated with altered PM and CM processes (Ullsperger, 




Permission. The study was approved by Swissmedic and Cantonal Ethics Committee of 
Zurich and registered at ClinicalTrials.gov (NCT02342366). According to the declaration of 
Helsinki all participants provided written informed consent. 
 
Study design. The study followed a placebo-controlled, randomized, balanced, cross-over 
design. Each subject attended a screening, two experimental days and a follow-up session, 
wherein experimental days were separated by a washout phase of seven days. 
 
Participants. Twenty healthy, male volunteers (mean age 25.8±5.1 years) participated in the 
study. The following criteria were required for inclusion: (i.) male sex in order to avoid the 
potential impact of menstrual cycle, (ii.) age within the range of 18 to 40 years, (iii.) absence 
of any somatic or psychiatric disorders, (iv.) no first-degree relatives with a history of 
psychiatric disorders, (v.) non-smoking, given the effects of nicotine on EEG signals (Franken 
et al, 2010), (vi.) without a history of drug abuse (lifetime use > 5 occasions, with exception 
of occasional cannabis use). None of the participants reported previous experiences with GHB 
in their life. Participants were instructed to abstain from ethanol 24 hours before the session 
and were asked to neither have breakfast nor drink caffeinated beverages in the morning of an 
experimental session, as bioavailability of GHB is markedly reduced when taken together 
with food (Borgen et al, 2004). Urine samples were collected on the two experimental days in 
order to ensure that all participants abstained from illegal substance use. All participants were 
instructed about potential risks concerning the administered substance and were monetarily 
compensated for the completion of the study. We previously reported effects of GHB on 
resting state EEG, pharmacokinetics, social cognition and mood in the same study sample 
(Von Rotz et al, 2017.; Liechti et al, 2016; Bosch et al, 2015). 
 
Drug administration. Each subject received either 20 mg/kg (N=10) or 35 mg/kg (N=10) of 
GHB (Xyrem®) dissolved in 3dl of orange juice and a placebo, matched in appearance and 
taste. The doses used were safe and tolerable and can be regarded as intermediate in intensity, 
characterized by significant subjective and cognitive effects. Undesired side effects such as 
vomiting or narcosis are unlikely to occur in this dosage range (Palatini et al, 1993; Abanades 




Eriksen-Flanker task. In a modified version of the Eriksen-Flanker task (Eriksen 1974) 
subjects were required to respond as fast and accurately as possible according to the direction 
pointed by a centrally presented arrow with either the index finger of the left hand (←) or the 
right hand (→), respectively. Two additional arrows flanking the target arrow on the left as 
well as the right side either favored the target response (congruent trials, ←←←←← or 
→→→→→) or primed the other response (incongruent trials, ←←→←← or →→←→→). 
The stimuli were presented on a black background for 650 ms. In order to assure a constant 
error rate throughout participants and to ensure a sufficient number of incorrect responses, the 
difficulty level during the task was programmed in a dynamic way. In the case of an error 
commission, presentation time was prolonged by 15 ms for the subsequent trial; in the case of 
a correct response, presentation time was shortened by 30 ms. Furthermore, visual feedback 
about the correctness of the response was given 3000 ms after the response, indicated by 
smiling (J) or sad faces (L), or by a question mark (?) if a response was too slow. The task 
consisted of 240 trials (120 congruent, 120 incongruent) and each of the four stimuli were 
presented in a randomized order. The task was performed between 70-90 min after 
GHB/placebo administration, which is shortly after peak drug effects (Abanades et al, 2006; 
Liechti et al, 2016). 
 
Blood samples. To determine the plasma kinetics of GHB post-administration, blood was 
withdrawn at minutes t-20, t35, t60, t100, t140, and t200 with the help of a permanent peripheral 
venous catheter. GHB was quantified in the plasma by liquid chromatography-mass 
spectrometry, according to the procedure of Meyer and colleagues (2011). As blood sampling 
was not feasible during the task execution, plasma values for the task time point (t70-t90) were 
estimated by averaging the plasma values at t60 and t100 (see supplementary figure 1). 
 
Subjective measurement. Subjective drug effects were monitored with a 4-dimensional 
Visual Analog Scale (VAS). Therein, the dimensions “general drug effect”, “sedation”, 
“stimulation” and “dizziness” were assessed on a scale ranging from zero (“no effect”) to ten 
(“strong effect”). The VAS was applied at time points t–15, t40, t60, t100, t120; and t180 minutes. 
	
EEG data acquisition. A BioSemi ActiveTwo electrode system (BioSemi, Netherlands) 
including 64 scalp electrodes was used for EEG recording. Additional electrooculographic 
electrodes were placed superior and lateral to the eyes in order to detect horizontal and 




EEG data preprocessing. EEG data preprocessing was performed using the Brain Vision 
Analyzer 2 software (Brain Products GmBH). First, channels with bad data quality were 
interpolated using spherical splines (Perrin, Pernier, Bertrand, and Echallier 1989). Second, 
the EEG data were re-referenced to the average of all scalp electrodes. Third, EEG data were 
bandpass-filtered from 0.5-40 Hz in order to attenuate channel drifts and to satisfy the 
stationarity assumption necessary for computing independent component analysis (ICA) 
(Onton and Makeig 2006). Fourth, an Ocular Correction ICA was applied to remove eye 
blinks as well as vertical and horizontal eye movements (Bell and Sejnowski 1995; Lee and 
Seung 1999).  
 
ERN, Correct-related negativity (CRN), N2. Response-locked ERP segments were generated 
based on the marker position of incorrect response (ERN) and correct responses (CRN) (-
1500 ms to 1500 ms). Moreover, stimulus-locked ERP segments were generated based on the 
marker position for congruent trials and for incongruent trials (-1500 ms to 1500 ms). The 
analysis was restricted to N2s preceding correct trials, wherein congruent (N2-con) and 
incongruent trials (N2-inc) were differentiated. Artifact-containing segments (maximal 
allowed amplitude difference: +/-100 µV, maximal allowed voltage step: 50 µV/ms, Lowest 
allowed activity: 0.5 µV) were automatically rejected from the data set. The remaining single 
trials were averaged within subjects (Avg_ERN, Avg_CRN, Avg_N2-con, Avg_N2-inc). 
Furthermore, to ensure interpretable ERPs, only subjects with at least 24 clean segments were 
included in the analysis. Therefore, one subject had to be excluded due to low data quality and 
4 subjects due to a low number of incorrect trials (<24). The final number of segments which 
were included in the analysis was: ERN (39.2±14.2), CRN (43.4±9.5), N2-con (74.8±15.3), 
N2-inc (42±7.1). The number of segments did not significantly differ between the drug 
conditions (p>0.05). Fifteen subjects thus entered the final analysis (low dose N=6, high dose 
N=9).  
ERN and CRN amplitudes were quantified by subtracting the most negative peak between 0 
to 150 ms post-response from the most positive peak -150 to 0 ms pre-response at electrode 
FCz, where ERN/CRN amplitudes were largest. For the N2 component, amplitudes were 
quantified by subtracting the most negative peak between 200 to 350 ms post-stimulus from 





Time-frequency analysis. To assess the time-frequency of neural oscillations, a continuous 
Morlet Complex Wavelet Transformation was applied to the 3s segments (segment window: -
1500 to 1500 ms around stimuli (N2-con/N2-inc) or response (ERN/CRN)) at the FCz 
electrode. Spectral power was calculated between 1-12 Hz (Delta (1-4 Hz), Theta (5-7 Hz), 
Alpha1 (8-10), Alpha2 (11-12 Hz)) using a Morlet parameter of 5.5 and Gabor-normalized 
instantaneous amplitudes. Single trial values were averaged within subjects and condition. 
Peak spectral values for each frequency band during a +/-100 ms time-window around the 
ERN/CRN or N2 peaks were exported for further analysis. Furthermore, the extent of 
normalized phase variability across trials for each condition was quantified by the phase-
locking value (Lachaux et al, 1999). This results in values ranging from 0 (randomized phases 
across trials) to 1 (consistent phase across trial).  
 
Prestimulus activity. To determine pre-stimuli frequency power, a continuous Morlet 
Complex Wavelet Transformation was applied to a 0.8 s epoch prior to stimulus presentation 
(segment window: -600 to 200 ms before stimulus presentation) at the FCz electrode. Spectral 
power was calculated between 1-12 Hz, using a Morlet parameter of 5.5 and Gabor-
normalized instantaneous amplitudes. Single trial wavelets were averaged within subjects and 
peak spectral wavelet values for each frequency band -600 to -200 ms prior to stimulus 
presentation were exported for further analysis. 
 
Statistical analysis. All analysis was conducted using RStudio Version 1.0.136 (RStudio, 
Inc.). Individual averages for 1) reaction time, 2) error rates, 3) post error slowing, 4) 
ERN/CRN amplitude, 5) N2 amplitudes, 6) spectral power and 7) Phase-locking factor (PLF) 
were entered in a Linear Mixed Effects Model (LME). Thus, possible factors were condition 
(GHB vs. Placebo), GHB_plasma (GHB plasma concentration), and furthermore correctness 




Behavioral data. Statistical analysis of behavioral data (F.1A-C) revealed a significant main 
effect of GHB_plasma (p<0.01) and congruency (p<0.001) on reaction times. Moreover, post-
hoc testing revealed that GHB prolonged reaction times only for congruent (p<0.05) and not 
for incongruent trials (p>0.05). Neither error rates (p>0.05) nor post-error slowing (p>0.05) 
were affected by the drug. 
 
 
Fig. 1 Means and standard error of means of behavioral parameter. (A) represents reaction times, 
depicted for congruent (con) and incongruent (inc) trials, (B) post-error slowing and (C) error rates. * 
represents significant GHB_plasma effect: * p < .05, ** p < .01, *** p < .001. 
#
 represents significant 
congruency effect: 
#
 p < .05, 
##
 p < .01, 
###
 p < .001. 
 
Response-locked potentials. Statistical analysis of response-locked potentials (F.2A-C) 
revealed a significant decreasing effect of GHB_plasma (p<0.05) on ERN (p<0.01) and CRN 
(p<0.05) amplitudes. Post-hoc testing revealed a decreasing effect of GHB_plasma on CRN 
(p<0.05) and ERN (p<0.01) amplitudes. Furthermore, there was a significant correctness 
effect (p<0.001), indicated by higher amplitude for incorrect compared to correct trials. 
 
Response-locked oscillations. Statistical analysis of response-locked spectral power values 
(F.2F) revealed a significant main GHB_plasma (p<0.05) and correctness (p<0.001) effect on 
response-locked spectral power. Post-hoc testing revealed a significant correctness effect on 
all investigated frequency ranges (delta (p<0.001), theta (p<0.001), alpha1 (p<0.001), alpha2 
(p<0.001)). Furthermore, we found a significant GHB_plasma effect on theta (p<0.05) and 
alpha1 (p<0.05) power for incorrect trials, and a trend-level decrease for correct trials in the 





Fig. 2 (A) CRN and (B) ERN with topographical maps thereof, depicted for the placebo (black) and 
GHB (red) condition. (C) Means and standard error of means of CRN and ERN amplitudes. (D) 
Correct and (E) incorrect response-locked spectral analysis for the placebo (PLA) and the GHB (GHB) 
condition. (F) Means and standard error of means of correct and incorrect response-locked spectral 
powers for delta, theta, alpha1 and alpha2 range. * represents significant GHB_plasma effect: 
.
 p< 0.1, 
* p < .05, ** p < .01, *** p < .001. 
#
 represents significant correctness effect: 
#
 p < .05, 
##





Stimulus-locked potentials. Statistical analysis of stimulus-locked potentials (F.3A-C) 
revealed a significant GHB_plasma effect (p<0.01) and no congruency effect on N2 
amplitudes (p>0.05). Furthermore, we found a significant increasing effect of GHB_plasma 
on N2-inc amplitudes (p<0.05), whereas, N2-con amplitudes were increased on a trend level 
(p=0.07043). 
 
Stimulus-locked oscillations. Statistical analysis of spectral power values (F.3D-F) revealed a 
significant main GHB-plasma (p<0.05) and congruency (p<0.05) effect on stimulus-locked 
spectral power. Post-hoc testing revealed a significant increasing effect of GHB_plasma on 
delta power for congruent trials (p<0.05) and a significant effect on alpha1 (p<0.05) power 
and a trend level decreasing effect on the theta (p=0.08793) for grouped congruent and 






Fig. 3 (A) N2-con and (B) N2-inc with topographical maps thereof, depicted for the placebo (black) 
and GHB (red) condition. (C) Means and standard error of means of N2-con and N2-inc amplitudes. 
(D) Congruent and (E) incongruent stimulus-locked spectra for the placebo and the GHB condition. 
(F) Means and standard error of means of congruent and incongruent stimulus-locked spectral powers 
for the delta, theta, alpha1 and alpha2 range. * represents significant GHB_plasma effect: 
.
 p< 0.1, * p 
< .05, ** p < .01, *** p < .001. 
#
 represents significant congruency effect: 
#
 p < .05, 
##
 p < .01, 
###
 p < 
.001. 
 
Response-locked Phase-locking. Statistical analysis revealed a main GHB_plasma (p<0.05), 
but no correctness (p>0.05) effect on PLF (F.4A). Post-hoc testing revealed a significant 
decreasing effect of GHB_plasma on PLF in the delta (p<0.001) and alpha2 (p<0.05) 
frequency ranges, but only for incorrect trials. 
 
Stimulus-locked Phase-locking Statistical analysis revealed a main GHB_plasma (p<0.05), 
but no congruency (p>0.05) effect on PLF (F.4B). Post-hoc testing revealed a significant 
increasing effect of GHB_plasma on PLF in the delta range (p<0.05) for incongruent trials 





Fig. 4 Means and standard error of means of (A) response-locked trials, depicted for correct (corr) and 
incorrect (incorr) and (B) stimulus-locked trials, depicted for congruent (con) and incongruent (inc) 
trials. PLFs are shown separately for the delta, theta, alpha1 and alpha2 range. * represents significant 
a GHB_plasma effect: * p < .05, ** p < .01, *** p < .001. 
 
Pre-Stimulus activity. Statistical analysis of pre-stimulus time-frequency analysis (F.5A-C) 
revealed a significant main GHB_plasma effect on spectral power values. Post-hoc testing 
revealed a significant increasing effect of GHB_plasma on all frequencies (delta (p<0.001), 
theta (p<0.001), alpha1 (p<0.01) and alpha2 (p<0.01)). 
 
 Fig. 5 Wavelet analysis of the prestimulus activity depicted for the placebo (A) and GHB condition 
(B). (C) Means and standard error of means of prestimulus spectral powers for the delta, theta, alpha1 





The current study revealed a significant effect of the GABABR agonist GHB on the 
neurophysiological correlates of PM and CM. GHB decreased the ERN and associated 
frontomedial oscillations in the theta/alpha1 range. Similarly, GHB reduced neural 
oscillations in the theta/alpha1 range associated with the N2 component, but intriguingly 
increased the N2 amplitude itself. Behavioral analysis revealed prolonged reaction times and 
unaffected error rates or post-error slowing under GHB. These effects were accompanied by 
mixed subjective effects of sedation, stimulation and euphoria as published previously (Bosch 
et al, 2015). 
Our data suggest a disrupting effect of GHB on PM as reflected by the reduced ERN 
magnitude. As reported in previous studies, the ERN component most likely derives from an 
amplitude increase and a phase-resetting of ongoing delta and theta oscillation after error 
commission (Trujillo & Allen 2007; Yordanova et al, 2004). Consistently, GHB also reduced 
spectral power in the theta/alpha1 range, as well as phase-locking in the delta range during 
error commission. As the blunting effect of GHB on these correlates was more pronounced 
for incorrect then correct responses, it seems likely that GHB particularly impairs the ability 
to detect the commission of errors and not PM in general. Furthermore, we found enhanced 
spectral power over all examined frequencies (1-12 Hz) after error commission, compared to 
correct trials. These findings further underpin the sensitivity of these frontomedial neural 
oscillators to erroneous responses (Yordanova et al, 2004). Interestingly, we found no 
differences in phase-locking between correct and incorrect responses, suggesting that the 
power of these oscillations is more decisive for error detection than phase-resetting, at least in 
the data at hand. Based on these findings we conclude that GHB disrupts PM by diminishing 
the ability to elevate phasic neural oscillations in response to an error, characterized by 
decreased power in the theta/alpha1 range and a reduced phase-locking of delta oscillations. 
These oscillatory effects most likely underlie the GHB-induced reduction in the ERN, as 
previous studies have revealed a close relationship between those oscillations and the ERN 
(Trujillo & Allen 2007; Yordanova et al, 2004). Several studies found the ACC to be the core 
neural structure involved in the generation of these neural rhythms (e.g., Gehring & 
Willoughby 2004). As assumed by the reinforcement learning theory, error commission 
produces a neural encoded error signal, which is transmitted to the ACC via a phasic decline 
in the tonic activity of mesencephalic dopaminergic neurons (Holroyd et al, 2002). 
Importantly, GHB has been shown repeatedly to substantially affect both the ACC and 
dopaminergic transmission (e.g. Bosch et al, 2017; Cruz et al, 2004). In the present study, 
	
	
GHB induced a tonic power increase in pre-stimulus frontomedial oscillations over all 
examined frequencies (1-12 Hz). Moreover, in a previously published electrical source 
localization analysis, we found an increase in resting-state alpha power in the ACC under 
GHB compared to placebo (Von Rotz et al, 2017). According to the work of Jensen and 
Mazaheri (2010) pre-stimulus alpha activity provides inhibition, therewith reducing the 
processing capabilities of a given area, an effect that has been shown to be mainly mediated 
by GABAergic interneurons. Consequently, GHB might reduce the ERN and associated 
oscillations by increasing the tone of the inhibitory alpha rhythm within the ACC 
The mechanisms underlying GHB’s effects on the waking EEG and ERP components, has not 
been investigated in detail so far. Anyhow, two possible pharmacological mechanisms seem 
particularly likely to account for the observed changes in the investigated ERPs and neural 
oscillations in this study. First, GHB might directly hyperpolarize neurons within the ACC by 
activating pre- and postsynaptic GABABR. The activation of presynaptic GABABR 
suppresses the release of numerous excitatory neurotransmitters, thus reducing the occurrence 
of excitatory postsynaptic potentials (Andresen et al, 2011). Additionally, the postsynaptic 
activation of GABABR directly hyperpolarizes the membrane by triggering the opening of G-
protein-coupled inwardly-rectifying potassium channels (Cruz et al, 2004). Secondly, GHB 
might indirectly modulate the activity of the ACC by its strong downstream effects on several 
neurotransmitter systems, including the noradrenergic, serotonergic, cholinergic, and 
dopaminergic system (Andresen et al, 2011). Given the established relationship between 
dopaminergic firing and the generation of the ERN, a modulation of the dopaminergic system 
by GHB seems to provide the most plausible explanation for the observed effects on PM in 
this study (Cruz et al, 2004; Holroyd et al, 2002). According to that, GHB may not disrupt 
PM due to its effects on the ACC, but by modulating the transmission of prediction errors by 
the MCDS. It is not yet clear, whether GHB enhances (Cruz et al, 2004) or decreases 
(Brancucci et al, 2004) dopaminergic output in terminal regions, but converging evidence 
indicates a dose-dependent, bi-directional modulation of mesolimbic dopamine release, with 
lower doses having a disinhibiting effect on dopaminergic neurons in the ventral tegmental 
area (VTA) and higher doses directly inhibiting dopaminergic neurons (Labouèbe et al, 2007). 
Considering the euphorogenic and stimulating effects of GHB observed in our subjects, it 
seems likely that the dose range used can be considered low enough to disinhibit 
dopaminergic transmission rather than inhibiting it. Consequently, we suggest that the 
resulting increase in tonic mesencephalic dopaminergic transmission could counter the ability 
	
	
to decrease dopaminergic signaling in response to errors, leading to a deteriorated generation 
of prediction errors and thus a reduced disinhibition of the ACC. Further studies employing a 
simultaneous administration of GHB and dopamine receptor antagonists may prove this 
assumption. 
In summary, our results of disrupted PM under GHB complement the findings of previous 
studies on the inhibiting effect of GABAAR agonists, such as benzodiazepines and ethanol, on 
the ERN (De Bruijn et al, 2004; Holroyd & Yeung 2003; Riba et al, 2005; Ridderinkhof et al, 
2002), demonstrating that GABABR agonism also has a suppressing effect on ERN-generating 
networks, despite its stimulant effects. 
We further explored the impact of GHB on neurophysiological correlates of CM. Against 
expectations, N2 amplitudes were found to be significantly higher in the GHB condition 
compared to the placebo condition, indicating enhanced conflict detection under GHB. 
Interestingly, GHB also reduced – but to a lesser extent – spectral power in the theta/alpha1 
range, similarly to the reduction observed for PM, implying an equally inhibiting effect of 
GABABR agonism on frontomedial oscillations, both during error commission and response 
conflict. This diverging effect on the N2 and associated spectral power might indicate that the 
N2 does not equally interrelate with frontomedial neural oscillations in the theta/alpha1 band, 
contrary to observations for the ERN.  
Moreover, we found no significant congruency effect on N2 amplitudes, prima facie implying 
a similar response conflict load for congruent and incongruent trials. Nevertheless, time-
frequency analysis revealed significantly higher spectral power (1-12 Hz) locked to 
incongruent than to congruent stimuli, demonstrating the sensitivity of these oscillations to 
conflict load (Yeung & Nieuwenhuis 2009). Again, we observed a dissociation of the N2 
component and corresponding neural oscillations, here in regard to their susceptibility to 
response conflict, providing further evidence supporting the view that the N2 does not equally 
rely on these oscillations, compared to the ERN. Based on our results, it seems likely that the 
neurophysiological relationship between the phase-locking and power of neural oscillations 
on the one hand, and evoked potentials on the other hand, might not be as straightforward 
across different ERP components as originally assumed. 
Interestingly, we found an increased phase-locking in the delta range, which is opposed to the 
reduction seen during error commission. Besides its involvement during error detection 
(Yordanova et al, 2004), delta band activity has also been associated with target detection 
	
	
(Schurmann et al, 2001). From this point of view, such a delta increase might be indicative of 
an increased salience of the target stimuli. This view is supported by our recent neuroimaging 
studies, where GHB was found to activate the salience network (SN), a network involved in 
the detection of relevant internal and external stimuli to manage adaptive behavior (Bosch et 
al, 2018).  The SN is anchored in the anterior insula and the dorsal ACC as well as in 
subcortical structures such as the ventral striatum and nucleus accumbens and the VTA 
(Menon, 2011, 2015; Menon and Uddin, 2010). 
Taking the response conflict theory into account, similar drug effects on both PM and CM 
would be expected, as this theory suggests that the same neural ERP-generating mechanisms 
underlie the ERN and the N2 (Botvinick et al, 2001). However, our data revealed that GHB 
differently affects PM and CM at the electrophysiological level. Thereby, these results 
support the view of previous neuroimaging studies investigating PM and CM, where spatially 
distinct substructures within the medio-frontal cortex were found to be responsible either for 
PM or CM (Ullsperger and Von Cramon, 2001). Previous studies have revealed dissociative 
drug effects on the ERN and the N2 but, to our knowledge, GHB is the only drug reported so 
far to elicit opposite effects on the ERN and the N2. This divergence might reflect or underpin 
the different cognitive functions of the ERN and the N2. One prominent theory states that, 
while the ERN stems from the processing of implicit target stimulus information, the N2 
rather deals explicitly with the processing of external stimulus information (Yeung & Cohen 
2006). This view is consistent with our above suggestion that GHB’s increasing effect on the 
activity within the SN could account for an increase in the experienced salience of external 
stimuli, resulting in increased N2 amplitudes. Regarding the ERN, it seems likely that GHB – 
with its positive effects on mood – decreases the affective valence of negative internal 
information, resulting in a blunted ERN (Bosch et al, 2015). Conclusively, our results indicate 
that GHB has a distinctly different effect on CM than that of the GABAAR agonistic 
benzodiazepines or ethanol (Riba et al, 2005b; Ridderinkhof et al, n.d.). 
The present study bears a number of limitations: our sample size was moderate and limited to 
male subjects. However, we initially investigated 20 individuals, but because of data quality 
control reasons we had to exclude 5 participants. Since PM and CM were assessed between 
70 to 90 minutes after GHB ingestion, our findings may not reflect peak drug effects. 
Nevertheless, subjective drug effects were still present in the time window of data assessment, 
indicating that our findings still reflect GABABR effects. Finally, in our discussion we 
attribute the effects mainly to the GABABR, although GHB also has agonistic properties at the 
	
	
GHB receptor. However, it has been shown that the behavioral effects of exogeneously 





The present study reveals a dissociating effect of the GABAB-/GHB-R agonist GHB on the 
neurophysiological correlates of PM and CM, reflected in decreased PM and inverse effects 
on CM. Reduced PM most likely derives from a disrupted transmission of prediction errors to 
the ACC, caused by a tonic increase of mesencephalic dopaminergic signaling. Elevated CM, 
conversely, may stem from GHB’s ability to increase the visual salience of external stimuli. 
These effects resemble those observed for ethanol and benzodiazepines, with a distinct 
difference regarding an enhancing effect of GHB on the N2. Therefore, GHB is the first drug 
reported so far to have diverging effects on the neurophysiological correlates of PM and CM, 
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Fig. S1 Mean and standard error of mean GHB plasma values in nmol/mL for all three dosage levels. 
Paired t-tests used for comparison of GHB with placebo condition: * p < .05, ** p < .01, *** p < .001. 
All p-values are corrected for multiple comparisons by Holm’s sequential rejective procedure. Time 
point of EEG acquisition is depicted in green. 
	
Table S1: Table of F-values (degrees if freedom) derived from repeated measures ANOVA for 
all items of the VAS and GHB blood plasma levels with “drug” and “time” as factors.* p < .05, 







“drug * time“ 
Residual sum 
 squared 
VAS     
general drug effect 30.39(1)*** 13.29(5)*** 4.73(5)** 387.83 
sedation 23.08(1)*** 7.47(5)*** 3.45(5)* 518.20 
stimulation 6.00(1) 5.83(5)*** 2.92(5) 468.79 
dizziness 17.37(1)*** 6.90(5)*** 5.97(5)*** 218.56 
GHB     
Blood plasma 237.92(2)*** 47.75(5)*** 27.32(10)*** 37956 
 
